Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-01

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to determine whether a modified fasting protocol can reduce the potential risk of aspiration for patients currently prescribed GLP1-RAs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia

NCT06654219

Pulmonary Aspiration

RECRUITING NA

Effect of Fasting Recommendations Among Patients Using GLP-1 Receptor Agonists

NCT06839248

Residual Gastric Contents Pulmonary Aspiration of Gastric Contents

RECRUITING NA

GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy

NCT05875636

Gastric Content Aspiration

COMPLETED

GLP_1 RA Ultrasound Study

NCT06581120

Glucagon Like Peptide-1 (GLP-1 Delayed Gastric Emptying Risk of Aspiration +2 more

ENROLLING_BY_INVITATION

Effects of GLP-1 Agonists on Gastric Volume

NCT05854979

Diabetes Gastric Content Aspiration Glucagon-like Peptide 1 +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall objective of this project is to identify a reasonable means by which patients on GLP1-RAs can be safely cared for in the perioperative period that can be agreed upon by all groups involved in perioperative patient care. This will be assessed in patients undergoing upper endoscopy specifically since assessment of gastric contents would be minimally invasive for this patient population receiving anesthetic care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Upper Endoscopy GLP1-R-related Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This study has 3 arms, but two of them are historical cohorts (i.e. previous patients who have already been taken care of). One group will consist of patients who are not on GLP1 medications who underwent upper endoscopy, and another group will consist of patients who are on GLP1 medications who underwent upper endoscopy. The third group is the prospective group who are being enrolled and recruited - this group will consist of patients who are on GLP1 medications who abide by a modified fasting guideline consisting of a full-liquid diet 48 hours prior to procedure, clear liquid diet 24 hours prior to procedure, and no liquids or solids after midnight on the day of upper endoscopy.

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal fasting guidelines and not taking GLP1-RAs

Patients who are not taking GLP1 RAs (Receptor Agonists) and who will abide by the normal fasting guidelines

Group Type NO_INTERVENTION

No interventions assigned to this group

Normal fasting guidelines with GLP1-RAs

Patients who are taking GLP1 RAs (Receptor Agonists) for either diabetes or weight loss management who will abide by normal fasting guidelines

Group Type NO_INTERVENTION

No interventions assigned to this group

Modified fasting guidelines with GLP1-RAs

Patients who are prescribed and taking GLP1 RAs (Receptor Agonists) for either diabetes or weight loss management who follow the modified fasting guidelines. Modified fasting consists of a full-liquid diet 48 hours prior to the procedures, clear liquid diet 24 hours prior to their procedure, and nothing by mouth (NPO) after midnight on the day of their procedure.

Group Type EXPERIMENTAL

Modified Fasting Guidelines

Intervention Type OTHER

Patients will follow a full-liquid diet 48 hours prior to their procedure, clear liquid diet 24 hours prior to their procedure, and nothing by mouth (NPO) after midnight on the day of their procedure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Modified Fasting Guidelines

Patients will follow a full-liquid diet 48 hours prior to their procedure, clear liquid diet 24 hours prior to their procedure, and nothing by mouth (NPO) after midnight on the day of their procedure

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing elective upper endoscopy with gastroenterology team

Exclusion Criteria

* Urgent or emergent procedure
* Inclusion of colonoscopy or antegrade small bowel enteroscopy in planned procedure
* Upper GI barium study performed in past 24 hours.
* Gastroparesis
* Achalasia
* Pancreatitis
* Use of outpatient pro-motility medications
* Patient refusal
* Inability for patient to provide own consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No